Mitochondria-targeting particles

Papers of special note have been highlighted as: • of interest; •• of considerable interest.

References

• 1 Wang B, Galliford CV, Low PS. Guiding principles in the design of ligand-targeted nanomedicines. Nanomedicine (Lond.) 9(2), 313–330 (2014).
  CASGoogle Scholar
• 2 Martinho N, Damge C, Reis C. Recent advances in drug delivery systems. J. Biomater. Nanobiotechnol. 2(5A), 510–526 (2011).
  CASGoogle Scholar
• 3 Weissig V, Boddapati SV, Jabr L, D'Souza GG. Mitochondria-specific nanotechnology. Nanomedicine (Lond.) 2(3), 275–285 (2007).
  CASGoogle Scholar
• 4 Murphy MP, Smith RA. Drug delivery to mitochondria: the key to mitochondrial medicine. Adv. Drug Deliv. Rev. 41(2), 235–250 (2000).
  Medline CASGoogle Scholar
• 5 Bayeva M, Gheorghiade M, Ardehali H. Mitochondria as a therapeutic target in heart failure. J. Am. Coll. Cardiol. 61(6), 599–610 (2013).
  Medline CASGoogle Scholar
• 6 Moreira PI, Zhu X, Wang X et al. Mitochondria: atherapeutic target in neurodegeneration. Biochim. Biophys. Acta 1802(1), 212–220 (2010).
  Medline CASGoogle Scholar
• 7 Taylor RW, Turnbull DM. Mitochondrial DNA mutations in human disease. Nat. Rev. Genet. 6(5), 389–402 (2005).
  Medline CASGoogle Scholar
• 8 Walters AM, Porter GA Jr, Brookes PS. Mitochondria as a drug target in ischemic heart disease and cardiomyopathy. Circ. Res. 111(9), 1222–1236 (2012).
  Medline CASGoogle Scholar
• 9 Joiner ML, Koval OM, Li J et al. CaMKII determines mitochondrial stress responses in heart. Nature 491(7423), 269–273 (2012).
  Medline CASGoogle Scholar
• 10 Pradelli LA, Beneteau M, Ricci JE. Mitochondrial control of caspase-dependent and -independent cell death. Cell Mol. Life Sci. 67(10), 1589–1597 (2010).
  Medline CASGoogle Scholar
• 11 Szeto HH, Schiller PW. Novel therapies targeting inner mitochondrial membrane – from discovery to clinical development. Pharm. Res. 28(11), 2669–2679 (2011).
  Medline CASGoogle Scholar
• 12 Kinnally KW, Peixoto PM, Ryu S-Y, Dejean LM. Is mPTP the gatekeeper for necrosis, apoptosis, or both? Biochim. Biophys. Acta 1813(4), 616–622 (2011).
  Medline CASGoogle Scholar
• 13 Dumont M, Lin MT, Beal MF. Mitochondria and antioxidant targeted therapeutic strategies for Alzheimer's disease. J. Alzheimers Dis. 20(Suppl. 2), S633–S643 (2010).
  MedlineGoogle Scholar
• 14 Jin H, Kanthasamy A, Ghosh A, Anantharam V, Kalyanaraman B, Kanthasamy AG. Mitochondria-targeted antioxidants for treatment of Parkinson's disease: preclinical and clinical outcomes. Biochim. Biophys. Acta 1842(8), 1282–1294 (2013).
  MedlineGoogle Scholar
• 15 Reddy PH. Mitochondrial medicine for aging and neurodegenerative diseases. Neuromolecular Med. 10(4), 291–315 (2008).
  Medline CASGoogle Scholar
• 16 Moreira PI, Zhu X, Wang X et al. Mitochondria: a therapeutic target in neurodegeneration. Biochim. Biophys. Acta 1802(1), 212–220 (2010).
  Medline CASGoogle Scholar
• 17 Uttara B, Singh AV, Zamboni P, Mahajan RT. Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr. Neuropharmacol. 7(1), 65–74 (2009).
  Medline CASGoogle Scholar
• 18 Rohlena J, Dong LF, Ralph SJ, Neuzil J. Anticancer drugs targeting the mitochondrial electron transport chain. Antioxid. Redox Signal. 15(12), 2951–2974 (2011).
  Medline CASGoogle Scholar
• 19 Ferrin G, Linares CI, Muntane J. Mitochondrial drug targets in cell death and cancer. Curr. Pharm. Des. 17(20), 2002–2016 (2011).
  Medline CASGoogle Scholar
• 20 Wang F, Ogasawara MA, Huang P. Small mitochondria-targeting molecules as anti-cancer agents. Mol. Aspects Med. 31(1), 75–92 (2010).
  Medline CASGoogle Scholar
• 21 Marullo R, Werner E, Degtyareva N et al. Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions. PLoS One 8(11), e81162 (2013).
  MedlineGoogle Scholar
• 22 Sakhrani NM, Padh H. Organelle targeting: third level of drug targeting. Drug Des. Devel. Ther. 7, 585–599 (2013).
  Medline CASGoogle Scholar
• 23 Birk AV, Liu S, Soong Y et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J. Am. Soc. Nephrol. 24(8), 1250–1261 (2013).
  Medline CASGoogle Scholar
• 24 Chakrabarti AK, Feeney K, Abueg C et al. Rationale and design of the EMBRACE STEMI study: a Phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability and efficacy of intravenous Bendavia on reperfusion injury in patients treated with standard therapy including primary percutaneous coronary intervention and stenting for ST-segment elevation myocardial infarction. Am. Heart J. 165(4), 509–514.e7 (2013).
  Medline CASGoogle Scholar
• 25 Smith RA, Merphy MP. Mitochondria-targeted antioxidants as therapies. Discov. Med. 11(57), 106–114 (2011).
  MedlineGoogle Scholar
• 26 Smith RA, Porteous CM, Gane AM, Murphy MP. Delivery of bioactive molecules to mitochondria in vivo. Proc. Natl Acad. Sci. USA 100(9), 5407–5412 (2003).
  Medline CASGoogle Scholar
• 27 Mao P, Manczak M, Shirendeb UP, Reddy PH. MitoQ, a mitochondria-targeted antioxidant, delays disease progression and alleviates pathogenesis in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis. Biochim. Biophys. Acta 1832(12), 2322–2331 (2013).
  Medline CASGoogle Scholar
• 28 Miquel E, Cassina A, Martinez-Palma L et al. Neuroprotective effects of the mitochondria-targeted antioxidant MitoQ in a model of inherited amyotrophic lateral sclerosis. Free Radic. Biol. Med. 70, 204–213 (2014).
  Medline CASGoogle Scholar
• 29 Smith RA, Murphy MP. Animal and human studies with the mitochondria-targeted antioxidant MitoQ. Ann. NY Acad. Sci. 1201, 96–103 (2010).
  Medline CASGoogle Scholar
• 30 Chamberlain GR, Tulumello DV, Kelley SO. Targeted delivery of doxorubicin to mitochondria. ACS Chem. Biol. 8(7), 1389–1395 (2013).
  Medline CASGoogle Scholar
• 31 Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J. Mol. Biol. 13(1), 238–252 (1965).
  Medline CASGoogle Scholar
• 32 Chang HI, Yeh MK. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int. J. Nanomedicine 7, 49–60 (2012).
  Medline CASGoogle Scholar
• 33 Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Deliv. Rev. 65(1), 36–48 (2013).
  Medline CASGoogle Scholar
• 34 Weissig V, Lasch J, Erdos G, Meyer HW, Rowe TC, Hughes J. DQAsomes: a novel potential drug and gene delivery system made from Dequalinium. Pharm. Res. 15(2), 334–337 (1998).• Early report on a mitochondria-specific particulate drug delivery system.
  Medline CASGoogle Scholar
• 35 Weissig V, Lizano C, Torchilin VP. Selective DNA release from DQAsome/DNA complexes at mitochondria-like membranes. Drug Deliv. 7(1), 1–5 (2000).
  Medline CASGoogle Scholar
• 36 Weissig V, D'souza GG, Torchilin VP. DQAsome/DNA complexes release DNA upon contact with isolated mouse liver mitochondria. J Control. Release 75(3), 401–408 (2001).
  Medline CASGoogle Scholar
• 37 D'souza GG, Rammohan R, Cheng SM, Torchilin VP, Weissig V. DQAsome-mediated delivery of plasmid DNA toward mitochondria in living cells. J Control. Release 92(1–2), 189–197 (2003).
  MedlineGoogle Scholar
• 38 Andre N, Carre M, Brasseur G et al. Paclitaxel targets mitochondria upstream of caspase activation in intact human neuroblastoma cells. FEBS Lett. 532(1–2), 256–260 (2002).
  Medline CASGoogle Scholar
• 39 D'souza GG, Cheng SM, Boddapati SV, Horobin RW, Weissig V. Nanocarrier-assisted sub-cellular targeting to the site of mitochondria improves the pro-apoptotic activity of paclitaxel. J. Drug Target. 16(7), 578–585 (2008).
  MedlineGoogle Scholar
• 40 Men Y, Wang XX, Li RJ et al. The efficacy of mitochondrial targeting antiresistant epirubicin liposomes in treating resistant leukemia in animals. Int. J. Nanomedicine 6, 3125–3137 (2011).
  Medline CASGoogle Scholar
• 41 Zhang L, Yao HJ, Yu Y et al. Mitochondrial targeting liposomes incorporating daunorubicin and quinacrine for treatment of relapsed breast cancer arising from cancer stem cells. Biomaterials 33(2), 565–582 (2012).•• Demonstrated both in vitro and in vivo cytotoxicity of mitochondrial-targeting liposomes toward breast cancer stem cells and provided a mechanistic explanation.
  Medline CASGoogle Scholar
• 42 Yu Y, Wang ZH, Zhang L et al. Mitochondrial targeting topotecan-loaded liposomes for treating drug-resistant breast cancer and inhibiting invasive metastases of melanoma. Biomaterials 33(6), 1808–1820 (2012).
  Medline CASGoogle Scholar
• 43 Collnot EM, Baldes C, Schaefer UF, Edgar KJ, Wempe MF, Lehr CM. Vitamin E TPGS P-glycoprotein inhibition mechanism: influence on conformational flexibility, intracellular ATP levels, and role of time and site of access. Mol. Pharm. 7(3), 642–651 (2010).
  Medline CASGoogle Scholar
• 44 Wang XX, Li YB, Yao HJ et al. The use of mitochondrial targeting resveratrol liposomes modified with a dequalinium polyethylene glycol-distearoylphosphatidyl ethanolamine conjugate to induce apoptosis in resistant lung cancer cells. Biomaterials 32(24), 5673–5687 (2011).
  Medline CASGoogle Scholar
• 45 Li N, Zhang CX, Wang XX et al. Development of targeting lonidamine liposomes that circumvent drug-resistant cancer by acting on mitochondrial signaling pathways. Biomaterials 34(13), 3366–3380 (2013).
  Medline CASGoogle Scholar
• 46 Carter LG, D'orazio JA, Pearson KJ. Resveratrol and cancer: a focus on in vivo evidence. Endocr. Relat. Cancer 21(3), R209–R225 (2014).
  Medline CASGoogle Scholar
• 47 Pan Y, Zhao W, Wang J, Liu Q, Yang G, Li J. [Establishment of a multidrug resistance cell line A549/cDDP of human lung adenocarcinoma and expression analysis of multidrug resistance-associated genes.]. Zhongguo Fei Ai Za Zhi 12(3), 187–192 (2009).
  Medline CASGoogle Scholar
• 48 Mullen TD, Obeid LM. Ceramide and apoptosis: exploring the enigmatic connections between sphingolipid metabolism and programmed cell death. Anticancer Agents Med. Chem. 12(4), 340–363 (2012).
  Medline CASGoogle Scholar
• 49 Boddapati SV, D'souza GG, Erdogan S, Torchilin VP, Weissig V. Organelle-targeted nanocarriers: specific delivery of liposomal ceramide to mitochondria enhances its cytotoxicity in vitro and in vivo. Nano Lett. 8(8), 2559–2563 (2008).
  Medline CASGoogle Scholar
• 50 Solomon MA, Shah AA, D'Souza GG. In vitro assessment of the utility of stearyl triphenyl phosphonium modified liposomes in overcoming the resistance of ovarian carcinoma Ovcar-3 cells to paclitaxel. Mitochondrion 13(5), 464–472 (2013).
  Medline CASGoogle Scholar
• 51 Biswas S, Dodwadkar NS, Deshpande PP, Torchilin VP. Liposomes loaded with paclitaxel and modified with novel triphenylphosphonium–PEG–PE conjugate possess low toxicity, target mitochondria and demonstrate enhanced antitumor effects in vitro and in vivo. J. Control. Release 159(3), 393–402 (2012).
  Medline CASGoogle Scholar
• 52 Patel NR, Hatziantoniou S, Georgopoulos A et al. Mitochondria-targeted liposomes improve the apoptotic and cytotoxic action of sclareol. J. Liposome Res. 20(3), 244–249 (2010).
  Medline CASGoogle Scholar
• 53 Zhou J, Zhao WY, Ma X et al. The anticancer efficacy of paclitaxel liposomes modified with mitochondrial targeting conjugate in resistant lung cancer. Biomaterials 34(14), 3626–3638 (2013).
  Medline CASGoogle Scholar
• 54 Wagle MA, Martinville LE, D'Souza GG. The utility of an isolated mitochondrial fraction in the preparation of liposomes for the specific delivery of bioactives to mitochondria in live mammalian cells. Pharm. Res. 28(11), 2790–2796 (2011).
  Medline CASGoogle Scholar
• 55 Yamada Y, Akita H, Kamiya H et al. MITO-Porter: aliposome-based carrier system for delivery of macromolecules into mitochondria via membrane fusion. Biochim. Biophys. Acta 1778(2), 423–432 (2008).
  Medline CASGoogle Scholar
• 56 Yasuzaki Y, Yamada Y, Harashima H. Mitochondrial matrix delivery using MITO-Porter, a liposome-based carrier that specifies fusion with mitochondrial membranes. Biochem. Biophys. Res. Commun. 397(2), 181–186 (2010).
  Medline CASGoogle Scholar
• 57 Kawamura E, Yamada Y, Harashima H. Mitochondrial targeting functional peptides as potential devices for the mitochondrial delivery of a DF-MITO-Porter. Mitochondrion 13(6), 610–614 (2013).
  Medline CASGoogle Scholar
• 58 Yamada Y, Furukawa R, Yasuzaki Y, Harashima H. Dual function MITO-Porter, a nano carrier integrating both efficient cytoplasmic delivery and mitochondrial macromolecule delivery. Mol. Ther. 19(8), 1449–1456 (2011).
  Medline CASGoogle Scholar
• 59 Khalil IA, Kogure K, Futaki S, Harashima H. High density of octaarginine stimulates macropinocytosis leading to efficient intracellular trafficking for gene expression. J. Biol. Chem. 281(6), 3544–3551 (2006).
  Medline CASGoogle Scholar
• 60 Yamada Y, Harashima H. Delivery of bioactive molecules to the mitochondrial genome using a membrane-fusing, liposome-based carrier, DF-MITO-Porter. Biomaterials 33(5), 1589–1595 (2012).
  Medline CASGoogle Scholar
• 61 Lu JM, Wang X, Marin-Muller C et al. Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev. Mol. Diagn. 9(4), 325–341 (2009).
  Medline CASGoogle Scholar
• 62 Vilar G, Tulla-Puche J, Albericio F. Polymers and drug delivery systems. Curr. Drug Deliv. 9(4), 367–394 (2012).
  Medline CASGoogle Scholar
• 63 Astete CE, Sabliov CM. Synthesis and characterization of PLGA nanoparticles. J. Biomater. Sci. Polym. Ed. 17(3), 247–289 (2006).
  Medline CASGoogle Scholar
• 64 Marrache S, Dhar S. Engineering of blended nanoparticle platform for delivery of mitochondria-acting therapeutics. Proc. Natl Acad. Sci. USA 109(40), 16288–16293 (2012).• Well characterized mitochondrial-targeting biodegradable polymeric delivery system.
  Medline CASGoogle Scholar
• 65 Mishra S, Palanivelu K. The effect of curcumin (turmeric) on Alzheimer's disease: an overview. Ann. Indian Acad. Neurol. 11(1), 13–19 (2008).
  MedlineGoogle Scholar
• 66 Potter PE. Curcumin: a natural substance with potential efficacy in Alzheimer's disease. J. Exp. Pharmacol. 5, 9 (2013).
  Google Scholar
• 67 Grundlingh J, Dargan PI, El-Zanfaly M, Wood DM. 2,4-dinitrophenol (DNP): a weight loss agent with significant acute toxicity and risk of death. J. Med. Toxicol. 7(3), 205–212 (2011).
  Medline CASGoogle Scholar
• 68 Rothblat GH, Phillips MC. High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr. Opin. Lipidol. 21(3), 229–238 (2010).
  Medline CASGoogle Scholar
• 69 Seimon T, Tabas I. Mechanisms and consequences of macrophage apoptosis in atherosclerosis. J. Lipid Res. 50(Suppl.), S382–S387 (2009).
  MedlineGoogle Scholar
• 70 Karaflou M, Lambrinoudaki I, Christodoulakos G. Apoptosis in atherosclerosis: a mini-review. Mini Rev. Med. Chem. 8(9), 912–918 (2008).
  Medline CASGoogle Scholar
• 71 Marrache S, Dhar S. Biodegradable synthetic high-density lipoprotein nanoparticles for atherosclerosis. Proc. Natl Acad. Sci. USA 110(23), 9445–9450 (2013).
  Medline CASGoogle Scholar
• 72 Marrache S, Tundup S, Harn DA, Dhar S. Ex vivo programming of dendritic cells by mitochondria-targeted nanoparticles to produce interferon-gamma for cancer immunotherapy. ACS Nano 7(8), 7392–7402 (2013).
  Medline CASGoogle Scholar
• 73 Dykman LA, Khlebtsov NG. Gold nanoparticles in biology and medicine: recent advances and prospects. Acta Naturae 3(2), 34–55 (2011).
  Medline CASGoogle Scholar
• 74 Ong C, Lim JZ, Ng CT, Li JJ, Yung LY, Bay BH. Silver nanoparticles in cancer: therapeutic efficacy and toxicity. Curr. Med. Chem. 20(6), 772–781 (2013).
  Medline CASGoogle Scholar
• 75 Dreaden EC, Austin LA, Mackey MA, El-Sayed MA. Size matters: gold nanoparticles in targeted cancer drug delivery. Ther. Deliv. 3(4), 457–478 (2012).
  Medline CASGoogle Scholar
• 76 Ma X, Wang X, Zhou M, Fei H. A mitochondria-targeting gold-peptide nanoassembly for enhanced cancer-cell killing. Adv. Healthc. Mater. 2(12), 1638–1643 (2013).
  Medline CASGoogle Scholar
• 77 Law B, Quinti L, Choi Y, Weissleder R, Tung CH. A mitochondrial targeted fusion peptide exhibits remarkable cytotoxicity. Mol. Cancer Ther. 5(8), 1944–1949 (2006).
  Medline CASGoogle Scholar
• 78 McCully JD, Levitsky S. The mitochondrial K(ATP) channel and cardioprotection. Ann. Thorac. Surg. 75(2), S667–S673 (2003).
  MedlineGoogle Scholar
• 79 Spivak MY, Bubnov RV, Yemets IM, Lazarenko LM, Tymoshok NO, Ulberg ZR. Development and testing of gold nanoparticles for drug delivery and treatment of heart failure: a theranostic potential for PPP cardiology. EPMA J. 4(1), 20 (2013).
  MedlineGoogle Scholar
• 80 Paunesku T, Vogt S, Lai B et al. Intracellular distribution of TiO₂-DNA oligonucleotide nanoconjugates directed to nucleolus and mitochondria indicates sequence specificity. Nano Lett. 7(3), 596–601 (2007).
  Medline CASGoogle Scholar
• 81 Wang Y, Zi XY, Su J et al. Cuprous oxide nanoparticles selectively induce apoptosis of tumor cells. Int. J. Nanomedicine 7, 2641–2652 (2012).
  Medline CASGoogle Scholar
• 82 Wang Y, Yang F, Zhang HX et al. Cuprous oxide nanoparticles inhibit the growth and metastasis of melanoma by targeting mitochondria. Cell Death Dis. 4, e783 (2013).
  Medline CASGoogle Scholar
• 83 Ragg R, Natalio F, Tahir MN et al. Molybdenum trioxide nanoparticles with intrinsic sulfite oxidase activity. ACS Nano 8(5), 5182–5189 (2014).
  Medline CASGoogle Scholar